Drug Discovery World

APRIL 11, 2023

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. AI-driven RNA Structure Exploration (PARSE) Atomic AI launched at the start of 2023 with a $35 million series a financing, having previously raised previously raised a $7 million in a seed round.

RNA 52

RNA Medicine Engineer Drugs 52

Pharmaceutical Technology

FEBRUARY 9, 2023

The collaboration is aimed at discovering and developing new advanced treatments for genitourinary (GU) tumours as well as other related serious diseases using ReviR’s RNA-targeted technologies. ReviR combines computational and high throughput drug discovery technologies to deliver advanced medicines to patients.

Development 241

Development RNA Gene Therapy Genetics 241

Pharmaceutical Technology

MAY 17, 2023

Chinook Therapeutics and Ionis Pharmaceuticals have entered a partnership to develop an antisense oligonucleotide (ASO) therapy to treat a rare, severe chronic kidney disease. The collaboration aims to discover, develop and commercialise an ASO therapy.

Development 246

Development Protein RNA Genetics 246

Pharmaceutical Technology

AUGUST 17, 2022

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Bio Pharma Dive

MARCH 14, 2023

The company’s name comes from its goal of developing drugs that only “switch” on in target cells, potentially enabling more precise therapies.

RNA 130

RNA Medicine Development Drugs 130

Drug Discovery World

JANUARY 10, 2023

Esperovax and Ginkgo Bioworks have agreed a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications. . Initially, the companies will work to develop circRNAs harbouring payloads to specifically target colorectal cancer by inducing cell death only in cancerous cells. .

RNA 52

RNA Development Gene Therapy Protein 52

Scienmag

JULY 6, 2022

Army scientists and industry partners were among the first to demonstrate that messenger RNA (mRNA)—the technology recently used in COVID-19 vaccines and others—could also be used to develop treatments for infectious diseases. Credit: Study: USAMRIID / […].

RNA 81

RNA Development Scientist Vaccination 81

Medical Xpress

NOVEMBER 22, 2022

Scientists at University of Florida (UF) Scripps Biomedical Research have developed a potential medicine for a leading cause of ALS and dementia that works by eliminating disease-causing segments of RNA. The compound restored the health of neurons in the lab and rescued mice with the disease.

RNA 76

RNA Scientist Genetics Development 76

Drug Discovery World

DECEMBER 12, 2023

KRRO-110 is designed to co-opt an endogenous enzyme Adenosine Deaminase Acting on RNA (ADAR) to repair a pathogenic single nucleotide variant (SNV) on RNA and restore production of normal A1AT. Selecting a development candidate for our AATD program is an important milestone for Korro, but more importantly, for patients.

RNA 52

RNA In-Vivo Genotype Genetics 52

Drug Discovery World

JANUARY 23, 2023

Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment.

RNA 98

RNA Genome Genomics Engineer 98

pharmaphorum

NOVEMBER 1, 2022

14th Annual RNA Therapeutics. Investigating the next generation of genetic medicine through RNA based therapies. RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases.

RNA 52

RNA Genetics Gene Editing In-Vitro 52

XTalks

SEPTEMBER 13, 2021

With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.

RNA 105

RNA Genetics Genetic Disease Medicine 105

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. The evolving field of genomic medicine.

Genome 92

Genome Genomics Medicine Development 92

Pharmaceutical Technology

FEBRUARY 15, 2023

The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. They can react with RNA and inactivate the RNA itself.” This involves monitoring the material in different conditions.

Bioassay 130

Bioassay Development RNA Drugs 130

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.

RNA 52

RNA Drugs Gene Silencing Vaccination 52

Outsourcing Pharma

FEBRUARY 24, 2022

The pharmaceutical companyâs Lilly Institute for Genetic Medicine reportedly will focus on developing RNA-based therapeutics in a âstate-of-the-artâ facility.

Genetics 52

Genetics Medicine Development RNA 52

XTalks

NOVEMBER 9, 2021

Perhaps popularized by the COVID-19 vaccines, RNA-based technologies now have the potential to become the next best pesticide to combat crop pests, like insects and fungal pathogens. Over the last year, researchers have been studying the effectiveness of RNA-based pesticides, and there are already a handful of sprays in the works.

RNA 98

RNA Gene Scientist Protein 98

Scienmag

DECEMBER 13, 2021

Philadelphia, December 13, 2021 – In a new study in The Journal of Molecular Diagnostics, published by Elsevier, investigators report on the design and testing of a breathalyzer, known as the Bubbler, that relies on viral RNA detection to diagnose SARS-CoV-2.

RNA 96

RNA Scientist Development Medicine 96

Drug Discovery World

JANUARY 26, 2023

Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round. Atomic AI is oriented at the cutting edge of AI, RNA, and structural biology.

RNA 52

RNA Engineer Drugs Medicine 52

pharmaphorum

OCTOBER 18, 2021

SMi Group’s 13th Annual Conference: RNA Therapeutics 2022. Bolstering the latest advances and opportunities in RNA-based medicine. Delve into the latest innovations in novel RNA delivery and target specificity. Engage in the growing advances and development of RNA tools for vaccines and anti-infectives.

RNA 52

RNA Drug Delivery Scientist Clinical Development 52

Pharma Mirror

APRIL 21, 2024

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

STAT News

NOVEMBER 14, 2022

Ionis Pharmaceuticals, the California company that turned RNA-targeting medicines from an unproven idea into blockbuster drugs, is now expanding into a new class of therapeutics that treat disease by editing DNA.    On Monday, the company announced a partnership with Metagenomi to kickstart these efforts.

Gene Editing 98

Gene Editing RNA Gene Drugs 98

Scienmag

MARCH 1, 2021

Credit: Johan Wingborg In recent years, techniques have been developed to treat diseases with what are known as oligonucleotide drugs, based on short DNA or RNA molecules.

Medicine 84

Medicine Development RNA DNA 84

BioPharma Reporter

SEPTEMBER 7, 2021

Moderna and the nonprofit Institute for Life Changing Medicines (ILCM) are collaborating to develop a new messenger RNA (mRNA) therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare disease.

Development 131

Development RNA Medicine Regulation 131

Medical Xpress

MARCH 21, 2023

Researchers at Lund University Faculty of Medicine have determined a novel mechanism linking the metabolism of ribonucleic acids, RNA, to the development of leukemia in myelodysplastic syndrome (MDS) patients.

RNA 72

RNA Regulation Medicine Development 72

Drug Discovery World

FEBRUARY 27, 2023

DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models. DS: How is Atomic AI “unlocking the next generation of RNA drug discovery”? What is unique about your engine?

RNA 52

RNA Engineer Life Science Drugs 52

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA 40

RNA Protein Genetics Gene Expression 40

BioPharma Reporter

MAY 10, 2021

Flagship Pioneering has unveiled Laronde: a platform company developing Endless RNA.

RNA 98

RNA Engineer Medicine Protein 98

pharmaphorum

MAY 11, 2021

Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body.

RNA 98

RNA Drugs Protein Immune Response 98

Bio Pharma Dive

NOVEMBER 14, 2022

The RNA drug developer is paying the richly-funded startup $80 million in a wide-ranging alliance that marks its first foray into DNA editing medicines.

Gene Editing 154

Gene Editing RNA DNA Gene 154

Drug Discovery World

AUGUST 1, 2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The post RNA-based immunotherapy eradicates melanoma tumours appeared first on Drug Discovery World (DDW).

RNA 52

RNA Bioassay Genome Genomics 52

Drug Discovery World

DECEMBER 5, 2022

This represents a huge loss for both industry and the advance of medicine. LevitasBio will present how single-cell RNA sequencing has progressed the field of drug discovery and how upstream sample preparation methods that preserve cells in their native state is critical in identifying relevant biomarkers for drug discovery and development.

RNA 52

RNA Drugs Clinical Trials Clinical Trials 52

BioTech 365

JUNE 18, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Researchers develop most comprehensive RNA atlas to date.By

RNA 40

RNA Development Research Medicine 40

Pharmaceutical Technology

APRIL 26, 2023

MiNA Therapeutics has entered into a research collaboration and option licensing agreement with BioMarin Pharmaceutical to speed up the development of therapeutic ribonucleic acid activation (RNAa) candidates to treat rare genetic diseases. BioMarin may then license the assets fully to develop and commercialise them across the globe.

Development 130

Development Genetic Disease Genetics Gene Therapy 130

pharmaphorum

SEPTEMBER 1, 2020

The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. Why You Should Attend the RNA- Targeted Drug Discovery Summit. The post 3rd RNA-Targeted Drug Discovery Summit appeared first on.

RNA 52

RNA Drugs Protein Clinical Development 52

pharmaphorum

SEPTEMBER 28, 2021

The 4th RNA-Targeted Drug Discovery Summit is returning once again this December, to reunite the largest community of thought leaders and experts in biology, chemistry and RNA therapeutics to discuss cutting-edge small molecule strategies capable of interacting with and modulating RNA with improved specificity, selectivity and drug-like properties.

RNA 52

RNA Drugs Clinical Development Development 52

Pharmaceutical Technology

APRIL 20, 2023

Targovax has unveiled plans to rebrand as Circio , reflecting its strategic shift to focus on expediting the development of its innovative circular RNA (circRNA) platform. Initially reported in 2011, CircRNA is a naturally occurring class of RNA.

Gene Therapy 240

Gene Therapy RNA Gene Engineer 240